UCB SA

Report azionario ENXTBR:UCB

Capitalizzazione di mercato: €44.9b

UCB Crescita futura

Criteri Future verificati 3/6

UCB prevede che gli utili e i ricavi cresceranno rispettivamente di 17.3% e 9.7% all'anno. Si prevede che l'EPS crescerà di 17.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.3% in 3 anni.

Informazioni chiave

17.3%

Tasso di crescita degli utili

17.61%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili10.7%
Tasso di crescita dei ricavi9.7%
Rendimento futuro del capitale proprio19.34%
Copertura analitica

Good

Ultimo aggiornamento08 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento dell'analisi • Apr 30

UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside

The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.
Aggiornamento dell'analisi • Apr 16

UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile

Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.
Aggiornamento dell'analisi • Apr 01

UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance

Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.
Aggiornamento dell'analisi • Mar 18

UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance

The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
Aggiornamento dell'analisi • Mar 04

UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price

We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.
Aggiornamento dell'analisi • Feb 18

UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance

Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.
Aggiornamento dell'analisi • Feb 04

UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution

Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.
Aggiornamento dell'analisi • Jan 21

UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential

Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.
Aggiornamento dell'analisi • Jan 07

UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise

Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.
Aggiornamento dell'analisi • Dec 18

UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside

UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.
Aggiornamento dell'analisi • Dec 04

UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential

UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.
Aggiornamento dell'analisi • Nov 20

UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher

Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.
Articolo di analisi • Nov 11

UCB (EBR:UCB) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Aggiornamento dell'analisi • Nov 06

UCB: Strong Profit Margins And Momentum Will Drive Shares Higher

UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.
Aggiornamento dell'analisi • Oct 22

Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts

UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.
Articolo di analisi • Oct 14

Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...
Aggiornamento dell'analisi • Oct 08

Aging Populations And Emerging Markets Will Unlock Opportunity

UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.
Aggiornamento dell'analisi • Sep 24

Aging Populations And Emerging Markets Will Unlock Opportunity

The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.
Aggiornamento dell'analisi • Aug 27

Aging Populations And Emerging Markets Will Unlock Opportunity

Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.
Articolo di analisi • Jul 17

UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
User avatar
Nuova analisi • Mar 02

BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology

UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.

Previsioni di crescita degli utili e dei ricavi

ENXTBR:UCB - Stime future degli analisti e dati finanziari passati (EUR Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202810,6692,8273,1523,68516
12/31/20279,5312,2642,5623,02517
12/31/20268,4571,7621,9432,40017
12/31/20257,7411,5581,8422,291N/A
9/30/20257,2951,4451,5141,934N/A
6/30/20256,8481,3321,1851,576N/A
3/31/20256,5001,1991,0531,409N/A
12/31/20246,1521,0659201,242N/A
9/30/20245,8036537451,066N/A
6/30/20245,454240569889N/A
3/31/20245,318292507825N/A
12/31/20235,182343445761N/A
6/30/20235,111332620975N/A
3/31/20235,2793766841,047N/A
12/31/20225,4474207481,119N/A
6/30/20225,8548879821,462N/A
3/31/20225,8169711,0211,508N/A
12/31/20215,7771,0551,0601,553N/A
9/30/20215,6479969071,371N/A
6/30/20215,5179367541,188N/A
3/31/20215,4328347431,135N/A
12/31/20205,3477327321,081N/A
6/30/20205,198743706908N/A
3/31/20205,056767647895N/A
12/31/20194,913790588882N/A
6/30/20194,686652N/A950N/A
3/31/20194,659722N/A1,020N/A
12/31/20184,632792N/A1,089N/A
6/30/20184,569872N/A1,092N/A
3/31/20184,522812N/A1,010N/A
12/31/20174,474752N/A927N/A
9/30/20174,400708N/AN/AN/A
6/30/20174,325664N/A780N/A
3/31/20174,236604N/A604N/A
12/31/20164,147543N/A427N/A
9/30/20164,051439N/AN/AN/A
6/30/20163,955334N/A66N/A
3/31/20163,916299N/A156N/A
12/31/20153,876264N/A246N/A
9/30/20153,773266N/A388N/A
6/30/20153,670268N/A530N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di UCB ( 17.3% all'anno) è superiore al tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Si prevede che gli utili di UCB ( 17.3% all'anno) cresceranno più rapidamente del mercato Belgian ( 13.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di UCB cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di UCB ( 9.7% all'anno) crescerà più rapidamente del mercato Belgian ( 6.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di UCB ( 9.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di UCB sarà basso tra 3 anni ( 19.3 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/11 13:40
Prezzo dell'azione a fine giornata2026/05/11 00:00
Utili2025/12/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

UCB SA è coperta da 40 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Charles PitmanBarclays
Brian BourdotBarclays
Charles PitmanBarclays